IVE vs RGAGX: 23% overlap
iShares S&P 500 Value ETF and American Funds Growth Fund of America R6 share 22.9% of their portfolios by weight — computed as Σ min(wA, wB) over every holding both funds own.
Different holding dates. These holdings were published about 5 months apart — RGAGX as of 2026-02-28, the rest through 2026-07-23. Each fund is compared using its most recent file, so any trading in between shows up as a difference.
You would hold two tickers and get the diversification of 1.8. Two funds that shared nothing would score 2.0; two identical funds score 1.0.
Top shared holdings
IVE and RGAGX hold 133 of the same securities. The ten contributing most to the overlap figure:
| Holding | in IVE | in RGAGX | Δ |
|---|---|---|---|
| AMZN | 3.7% | 2.9% | 0.8% |
| AAPL | 8.1% | 1.8% | 6.2% |
| TSLA | 1.2% | 2.6% | 1.4% |
| V | 0.9% | 0.8% | 0.1% |
| GE | 0.6% | 1.1% | 0.5% |
| INTC | 1.6% | 0.5% | 1.1% |
| COST | 1.4% | 0.5% | 0.9% |
| MA | 0.5% | 0.9% | 0.4% |
| PM | 0.4% | 0.9% | 0.5% |
| VRTX | 0.4% | 2.1% | 1.7% |
Where IVE and RGAGX differ
Sector weights as a share of each fund, ordered by the size of the gap rather than the size of the sector — two funds that overlap heavily still usually diverge somewhere.
| Sector | IVE | RGAGX | Δ |
|---|---|---|---|
| Information Technology | 19.8% | 30.6% | −10.8pp |
| Communication Services | 2.9% | 13.2% | −10.4pp |
| Financials | 16.1% | 6.5% | +9.6pp |
| Unclassified | 0.0% | 7.6% | −7.6pp |
| Consumer Staples | 8.7% | 2.4% | +6.3pp |
| Energy | 7.4% | 1.9% | +5.4pp |
| Utilities | 4.5% | 0.5% | +4.0pp |
| Consumer Discretionary | 9.6% | 12.7% | −3.1pp |
Δ is IVE minus RGAGX, in percentage points. Sector data is not published by every issuer, so “Unclassified” is a real category rather than a gap in the table.
What each fund holds alone
42.3% of IVE by weight, held in no part of RGAGX.
66.0% of RGAGX by weight, held in no part of IVE.
A large count with a small weight is the usual shape: the positions one fund adds are typically its smallest ones.
Concentration and cost
| IVE | RGAGX | |
|---|---|---|
| Top 10 holdings | 23.7% | 36.7% |
| Positions held | 440 | 309 |
| Cost per $10,000 held, per year | $18 | $30 |
Cost is the expense ratio applied to $10,000; it excludes any brokerage commission, bid-ask spread or tax consequence. Figures are facts about the funds, not a suggestion about which to hold.
Frequently asked
How much do IVE and RGAGX overlap?
IVE and RGAGX overlap 22.9% by portfolio weight — moderate overlap. They share 133 holdings. The figure comes from current issuer holdings files (IVE as of 2026-07-23, RGAGX as of 2026-02-28).
How is the overlap between IVE and RGAGX calculated?
As the sum of the smaller weight in each fund, over every holding both funds own: Σ min(wA, wB). If IVE holds a stock at 6% and RGAGX holds the same stock at 4%, 4% counts as shared. The result is bounded between 0% and 100%, and it is computed after looking through any fund-of-funds to the underlying holdings.
Is it redundant to hold both IVE and RGAGX?
That depends on your goals — we state facts, not advice. At 22.9% overlap, each fund still contributes meaningfully distinct exposure.
What does IVE own that RGAGX doesn't?
IVE holds 440 positions and RGAGX holds 309; 306 of IVE's positions don't appear in RGAGX at all, and they are 42.3% of IVE by weight.
You probably hold more than two funds
This page compares IVE and RGAGX. Paste your whole portfolio — brokerage, 401(k), IRA — and see the overlap across every fund at once, plus what you actually own underneath them and your own Effective Funds number. Free, no account, nothing stored.
X-ray my portfolio — free →Watch IVE vs RGAGX
We re-read both funds’ published holdings every weeknight. Leave an address and we'll tell you when what's inside actually changes.
Not sending yet — email alerts are built but switched off, and you'll be among the first when they turn on. No spam, one-click unsubscribe.
Related comparisons
Sources: issuer holdings files, IVE as of 2026-07-23, RGAGX as of 2026-02-28. Weights are fractions of each fund. Diagnostics, not advice.